Fortress Biotech, Inc.
NASDAQ:FBIO · NASDAQ Capital Market
+$0.01 today
Vol 0.37M · Avg 0.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
13.7%
avg -529.3%
ROIC
-50.0%
avg -80.8%
ROA
3.7%
avg -27.4%
Analysis
ROE is currently the strongest return metric at 13.7% versus its period average of -529.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lindsay Allan Rosenwald | Executive Chairman, President & Chief Executive Officer | $687,665.00 | — | 71 | $4.59M | 13.81% |
David Jin | Chief Financial Officer & Head of Corporate Development | $664,075.00 | — | 35 | $1.25M | 3.77% |
Michael S. Weiss | Executive Vice Chairman of Strategic Development & Director | $652,665.00 | — | 60 | $2.28M | 6.85% |
Xiaoqin Lu | Chief Strategy Officer | $15,000.00 | — | 51 | $61,273.00 | 0.18% |
Samuel Berry | General Counsel & Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +51.2% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +51.2% (12yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Adagene Inc.
NASDAQ:ADAG
$134.41M
Gain Therapeutics, Inc.
NASDAQ:GANX
$71.66M
XBiotech Inc.
NASDAQ:XBIT
$71.34M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Nutriband Inc.
NTRB
$41.21M
CervoMed Inc.
CRVO
$22.68M
Who manages FBIO?
Fortress Biotech, Inc. (FBIO) lists 5 active executives. The top listed executive is Xiaoqin Lu, Chief Strategy Officer.
Are FBIO insiders buying or selling?
Recent insider activity shows net buying of $16.69M.
Explore More
Continue the stock analysis
Jump to another research area for this company.